Trial Profile
A Population-Weighted Estimate of Palivizumab Efficacy in Preventing RSV Hospitalizations among US High-Risk Children
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 May 2014
Price :
$35
*
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors MedImmune
- 20 May 2014 New trial record
- 03 May 2014 Results presented at the 2014 Annual Meeting of the Pediatric Academic Societies.